Teriflunomide in combination with beta-IFN: preliminary results


REPORT FROM THE 25th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  Teriflunomide is an immunosuppressant currently being tested in four large phase III trials in clinically isolated syndrome (estimated enrollment 780), MS with relapses (TEMSO trial, estimated n=1080), relapsing-remitting MS (planned n=1110) and versus beta-interferon-1a in RRMS (TENERE trial, estimated n=300).  The drug is the active metabolite of leflunomide that is used in the treatment of rheumatoid arthritis.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page